Latest Roche Hldg Ltd Spons (RHHBY) Headlines
Who Will Capture This $3.5 Billion Opportunity?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 10, 5:30PM CDT
Two of the most highly successful compounds to win FDA approval in the past few years have been Regeneron's Eylea and Novartis ' and Roche 's Lucentis. Both drugs help improve vision in patients who are losing their sight due to age or...
Label Expansion for Novartis' Xolair - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 4:30PM CST
Novartis received positive news when the European Commission (EC) approved Xolair for an additional indication.
Cancer Immunotherapy Race Stays Unpredictable
Amy Ho, The Motley Fool - Motley Fool - Fri Mar 07, 10:00AM CST
Cancer immunotherapy is a very hot field, and Bristol-Myers Squibb certainly took note, reallocating resources late last year to focus on the field, selling off its diabetes arm to AstraZeneca and ending new research in diabetes, hepatitis C and...
Encouraging Data from Roche - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 3:35PM CST
Roche (RHHBY) recently announced new encouraging data from phase IIb studies, LUTE / VERSE on asthma candidate lebrikizumab.
Can Roche Keep Its Bull Run Going?
Peter Stephens, The Motley Fool - Motley Fool - Thu Mar 06, 1:30PM CST
As one of the largest pharmaceutical stocks in the world and with one of the biggest pipelines in the business, Roche is bound to experience the odd disappointment every now and then. Indeed, recent news flow for the...
3 Big Battles in Biosimilars to Watch
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 05, 1:30PM CST
The global market for biosimilars, or generic versions of biologic medical products, is expected to soar to $24 billion by 2019, according to a recent report from Frost & Sullivan -- not bad for a fledgling industry that currently only consists...
Arrowhead Surges As Analysts Laud Hepatitis B Drug
at Investor's Business Daily - Wed Mar 05, 10:14AM CST
Biotech Arrowhead Research (ARWR), whose stock price had already doubled this year, jumped another 20% on the stock market today on a pair of bullish analyst initiation reports. After the close Tuesday, Michael Yee of RBC Capital Markets launched...
PDL BioPharma Misses on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:20AM CST
PDL BioPharma posted fourth-quarter 2013 earnings of 39 cents per share, below the Zacks Consensus Estimate of 41 cents.
Regeneron's Eylea: The Anatomy Of A Blockbuster Drug
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 04, 5:30PM CST
Few drugs become multi-billion blockbusters, but those that do usually have similar characteristics. They treat big, and growing patient populations; they don't compete with too many other drugs (and outperform those that they do); and they have...
Bristol Moving Ahead With Lung-Cancer Drug Combo
at Investor's Business Daily - Tue Mar 04, 3:01PM CST
An executive with Bristol-Myers Squibb (BMY) said Tuesday that the company is planning a phase-three trial of its drugs nivolumab and Yervoy to treat lung cancer. The company's stock rose nearly 6% on the news on the stock market today. At the Cowen...
Setback for Roche - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 2:55PM CST
Roche recently suffered a setback when it announced that an independent data monitoring committee has recommended that its phase III study, METLung, on onartuzumab (MetMab) should be stopped.
Synageva 4Q Loss Narrower-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 10:00AM CST
Synageva BioPharma Corp. (GEVA) reported fourth quarter 2013 loss of $1 per share, wider than the year-ago loss of 62 cents per share, but narrower than the Zacks Consensus Estimate of a loss of $1.02 per share.
Why Would Roche Return to the Antibiotics Market?
Amy Ho, The Motley Fool - Motley Fool - Tue Mar 04, 8:30AM CST
Antibiotics have long been viewed as a losing R&D game for pharmaceutical companies. The drugs are only used for short courses and usually offered at very affordable prices, meaning the sales per patient is pennies compared to the therapies for...
Today's Biggest Biotech Stories: Roche, Regeneron, Cell Therapeutics, and AstraZeneca
Leo Sun, The Motley Fool - Motley Fool - Mon Mar 03, 8:28AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four stocks -- Roche , Regeneron , ...
Genentech Provides Update on Phase III Study of Onartuzumab in People with Specific Type of Lung Cancer
Business Wire - Mon Mar 03, 12:01AM CST
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that an independent data monitoring committee has recommended that the Phase III METLung study be stopped due to a lack of clinically meaningful efficacy.
Halozyme's Q4 Loss Wider-Than-Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 1:43PM CST
Halozyme Therapeutics, Inc. (HALO) reported a fourth quarter loss of 19 cents per share, much wider than the year-ago loss of 4 cents per share and the Zacks Consensus Estimate of a loss of 17 cents per share. Lower revenues and higher costs led to the year-over-year increase in loss.
Concise Analysis of the International Genetic Testing Market
M2 - Fri Feb 28, 8:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/8z6k4n/global_genetic) has announced the addition of the "Concise Analysis of the International Genetic Testing Market" report to their offering. Currently, DTC genetic testing is the buzz word in the Global Genetic Testing market. DTC genetic testing refers to genetic tests that are marketed directly to consumers through television, print advertisements, or the internet. This form of testing, which is also called at-home genetic testing, provides access to a person's genetic information without the involvement of the consumer's healthcare provider. The DTC test typically includes collecting a DNA sample at home, often by swabbing the inside lining of the cheek, and mailing the sample back to the laboratory. Consumers are notified of their results by e-mail, over the phone, or the results are posted online on the websites of the offering companies. DTC genetic tests are expected to have a positive impact on the growth of the market during the forecast period. According to the report, one of the main drivers in this market is the increase in the aging population worldwide. The increasing prevalence of diseases such as diabetes, obesity, and cancer among the elderly population is contributing to the growth of the market. Further, the report states that one of the major challenges in the market is the lack of a credible standard procedure to evaluate the analytic and clinical validity of genetic tests. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis Companies Mentioned: - Abbott Laboratories - Agilent Technologies Inc. - Clarient Inc. - Genomic Health Inc. - Hologenic Inc. - Myriad Genetics Inc. - Qiagen N.V. - Quest Diagnostics Inc. - Roche Holding AG - Sequenom Inc. - Transgenomic Inc. - bioM?rieux SA For more information visit http://www.researchandmarkets.com/research/8z...al_genetic
AstraZeneca PLC's Renovation Plan Fully Underway
Stephen D., Simpson,, The Motley Fool - Motley Fool - Thu Feb 27, 5:30PM CST
Once a floundering big pharma with looming patent cliffs and a pitiful pipeline, CEO Pascal Soriot has remade AstraZeneca in a relatively short period of time. Patent cliffs are still likely to compress revenue for the next year, but AstraZeneca...
Abbott Labs Has Fallen and It Can't Get Up
at The Street - Thu Feb 27, 5:00AM CST
The promised growth from a spinoff of AbbVie has not materialized.
Narrower-than-Expected Loss at Curis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 12:30PM CST
Curis reported fourth quarter 2013 net loss per share of 5 cents, narrower than the Zacks Consensus Estimate of a loss of 7 cents.
Who Will Capture This $3.5 Billion Opportunity?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 10, 5:30PM CDT
Two of the most highly successful compounds to win FDA approval in the past few years have been Regeneron's Eylea and Novartis ' and Roche 's Lucentis. Both drugs help improve vision in patients who are losing their sight due to age or...
Label Expansion for Novartis' Xolair - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 4:30PM CST
Novartis received positive news when the European Commission (EC) approved Xolair for an additional indication.
Cancer Immunotherapy Race Stays Unpredictable
Amy Ho, The Motley Fool - Motley Fool - Fri Mar 07, 10:00AM CST
Cancer immunotherapy is a very hot field, and Bristol-Myers Squibb certainly took note, reallocating resources late last year to focus on the field, selling off its diabetes arm to AstraZeneca and ending new research in diabetes, hepatitis C and...
Encouraging Data from Roche - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 3:35PM CST
Roche (RHHBY) recently announced new encouraging data from phase IIb studies, LUTE / VERSE on asthma candidate lebrikizumab.
Can Roche Keep Its Bull Run Going?
Peter Stephens, The Motley Fool - Motley Fool - Thu Mar 06, 1:30PM CST
As one of the largest pharmaceutical stocks in the world and with one of the biggest pipelines in the business, Roche is bound to experience the odd disappointment every now and then. Indeed, recent news flow for the...
3 Big Battles in Biosimilars to Watch
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 05, 1:30PM CST
The global market for biosimilars, or generic versions of biologic medical products, is expected to soar to $24 billion by 2019, according to a recent report from Frost & Sullivan -- not bad for a fledgling industry that currently only consists...
Arrowhead Surges As Analysts Laud Hepatitis B Drug
at Investor's Business Daily - Wed Mar 05, 10:14AM CST
Biotech Arrowhead Research (ARWR), whose stock price had already doubled this year, jumped another 20% on the stock market today on a pair of bullish analyst initiation reports. After the close Tuesday, Michael Yee of RBC Capital Markets launched...
PDL BioPharma Misses on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:20AM CST
PDL BioPharma posted fourth-quarter 2013 earnings of 39 cents per share, below the Zacks Consensus Estimate of 41 cents.
Regeneron's Eylea: The Anatomy Of A Blockbuster Drug
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 04, 5:30PM CST
Few drugs become multi-billion blockbusters, but those that do usually have similar characteristics. They treat big, and growing patient populations; they don't compete with too many other drugs (and outperform those that they do); and they have...
Bristol Moving Ahead With Lung-Cancer Drug Combo
at Investor's Business Daily - Tue Mar 04, 3:01PM CST
An executive with Bristol-Myers Squibb (BMY) said Tuesday that the company is planning a phase-three trial of its drugs nivolumab and Yervoy to treat lung cancer. The company's stock rose nearly 6% on the news on the stock market today. At the Cowen...
Setback for Roche - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 2:55PM CST
Roche recently suffered a setback when it announced that an independent data monitoring committee has recommended that its phase III study, METLung, on onartuzumab (MetMab) should be stopped.
Synageva 4Q Loss Narrower-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 10:00AM CST
Synageva BioPharma Corp. (GEVA) reported fourth quarter 2013 loss of $1 per share, wider than the year-ago loss of 62 cents per share, but narrower than the Zacks Consensus Estimate of a loss of $1.02 per share.
Why Would Roche Return to the Antibiotics Market?
Amy Ho, The Motley Fool - Motley Fool - Tue Mar 04, 8:30AM CST
Antibiotics have long been viewed as a losing R&D game for pharmaceutical companies. The drugs are only used for short courses and usually offered at very affordable prices, meaning the sales per patient is pennies compared to the therapies for...
Today's Biggest Biotech Stories: Roche, Regeneron, Cell Therapeutics, and AstraZeneca
Leo Sun, The Motley Fool - Motley Fool - Mon Mar 03, 8:28AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four stocks -- Roche , Regeneron , ...
Genentech Provides Update on Phase III Study of Onartuzumab in People with Specific Type of Lung Cancer
Business Wire - Mon Mar 03, 12:01AM CST
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that an independent data monitoring committee has recommended that the Phase III METLung study be stopped due to a lack of clinically meaningful efficacy.
Halozyme's Q4 Loss Wider-Than-Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 1:43PM CST
Halozyme Therapeutics, Inc. (HALO) reported a fourth quarter loss of 19 cents per share, much wider than the year-ago loss of 4 cents per share and the Zacks Consensus Estimate of a loss of 17 cents per share. Lower revenues and higher costs led to the year-over-year increase in loss.
Concise Analysis of the International Genetic Testing Market
M2 - Fri Feb 28, 8:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/8z6k4n/global_genetic) has announced the addition of the "Concise Analysis of the International Genetic Testing Market" report to their offering. Currently, DTC genetic testing is the buzz word in the Global Genetic Testing market. DTC genetic testing refers to genetic tests that are marketed directly to consumers through television, print advertisements, or the internet. This form of testing, which is also called at-home genetic testing, provides access to a person's genetic information without the involvement of the consumer's healthcare provider. The DTC test typically includes collecting a DNA sample at home, often by swabbing the inside lining of the cheek, and mailing the sample back to the laboratory. Consumers are notified of their results by e-mail, over the phone, or the results are posted online on the websites of the offering companies. DTC genetic tests are expected to have a positive impact on the growth of the market during the forecast period. According to the report, one of the main drivers in this market is the increase in the aging population worldwide. The increasing prevalence of diseases such as diabetes, obesity, and cancer among the elderly population is contributing to the growth of the market. Further, the report states that one of the major challenges in the market is the lack of a credible standard procedure to evaluate the analytic and clinical validity of genetic tests. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis Companies Mentioned: - Abbott Laboratories - Agilent Technologies Inc. - Clarient Inc. - Genomic Health Inc. - Hologenic Inc. - Myriad Genetics Inc. - Qiagen N.V. - Quest Diagnostics Inc. - Roche Holding AG - Sequenom Inc. - Transgenomic Inc. - bioM?rieux SA For more information visit http://www.researchandmarkets.com/research/8z...al_genetic
AstraZeneca PLC's Renovation Plan Fully Underway
Stephen D., Simpson,, The Motley Fool - Motley Fool - Thu Feb 27, 5:30PM CST
Once a floundering big pharma with looming patent cliffs and a pitiful pipeline, CEO Pascal Soriot has remade AstraZeneca in a relatively short period of time. Patent cliffs are still likely to compress revenue for the next year, but AstraZeneca...
Abbott Labs Has Fallen and It Can't Get Up
at The Street - Thu Feb 27, 5:00AM CST
The promised growth from a spinoff of AbbVie has not materialized.
Narrower-than-Expected Loss at Curis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 12:30PM CST
Curis reported fourth quarter 2013 net loss per share of 5 cents, narrower than the Zacks Consensus Estimate of a loss of 7 cents.
